Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3

<p>Many tumour causing proteins, such as those expressed after chromosomal translocations or from point mutations, are intracellular and are not enzymes <em>per se</em> amenable to conventional drug targeting. We previously demonstrated an approach (<u>A</u>ntibody-anti...

全面介绍

书目详细资料
Main Authors: Chambers, J, Brend, T, Rabbitts, T
格式: Journal article
语言:English
出版: Nature Research 2019
实物特征
总结:<p>Many tumour causing proteins, such as those expressed after chromosomal translocations or from point mutations, are intracellular and are not enzymes <em>per se</em> amenable to conventional drug targeting. We previously demonstrated an approach (<u>A</u>ntibody-antigen <u>I</u>nteraction <u>D</u>ependent <u>A</u>poptosis (AIDA)) whereby a single anti-β-galactosidase intracellular single chain Fv antibody fragment, fused to inactive procaspase-3, induced auto-activation of caspase-3 after binding to the tetrameric β-galactosidase protein. We now demonstrate that co-expressing an anti-RAS heavy chain single VH domain, that binds to mutant RAS several thousand times more strongly than to wild type RAS, with a complementary light chain VL domain, caused programmed cell death (PCD) in mutant RAS expressing cells when each variable region is fused to procaspase-3. The effect requires binding of both anti-RAS variable region fragments and is RAS-specific, producing a tri-molecular complex that auto-activates the caspase pathway leading to cell death. AIDA can be generally applicable for any target protein inside cells by involving appropriate pairs of antigen-specific intracellular antibodies.</p>